Literature DB >> 16062084

Role of stereotactic radiosurgery in the treatment of brain metastases.

Lisa J Hazard1, Randy L Jensen, Dennis C Shrieve.   

Abstract

Stereotactic radiosurgery (SRS) is a highly conformal form of radiation therapy designed to deliver a high dose in a single treatment to the target volume while sparing adjacent normal tissues. Its role in the treatment of brain metastases continues to be defined, but the recently reported RTOG 95-08 trial demonstrated a survival benefit with the addition of SRS to whole-brain radiation therapy in select patients with a single brain metastasis, as well as a local control and palliative benefit in select patients with 1 to 3 brain metastases. The authors review the role of SRS in the treatment of brain metastases and discuss the use of SRS with or without whole-brain radiation therapy, optimal dose of SRS, SRS delivery methods, and selection of appropriate patients for SRS.

Entities:  

Mesh:

Year:  2005        PMID: 16062084     DOI: 10.1097/01.coc.0000158438.79665.bb

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  10 in total

1.  Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure.

Authors:  Haihong Yang; Xinyun Yang; Yalei Zhang; Xin Liu; Qiuhua Deng; Meiling Zhao; Xin Xu; Jianxing He
Journal:  Target Oncol       Date:  2014-07-02       Impact factor: 4.493

2.  Clinical factors associated with mortality within three months after radiosurgery of asymptomatic brain metastases from non-small cell lung cancer.

Authors:  Bina Kakusa; Summer Han; Sonya Aggarwal; Boxiang Liu; Gordon Li; Scott Soltys; Melanie Hayden Gephart
Journal:  J Neurooncol       Date:  2018-11-20       Impact factor: 4.130

3.  Erlotinib with pemetrexed/cisplatin for patients with EGFR wild-type lung adenocarcinoma with brain metastases.

Authors:  Yalei Zhang; Haihong Yang; Xinyun Yang; Qiuhua Deng; Meilin Zhao; Xin Xu; Jianxing He
Journal:  Mol Clin Oncol       Date:  2014-02-11

4.  Quick regression of brain metastases from lung adenocarcinoma with epidermal growth factor receptor-tyrosine kinase inhibitor treatment: A case report and literature review.

Authors:  Huaqiong Huang; Shuangli Zhu; Shaobin Wang; Wen Li
Journal:  Mol Clin Oncol       Date:  2016-06-02

5.  Image guidance for brain metastases resection.

Authors:  Sarah T Garber; Randy L Jensen
Journal:  Surg Neurol Int       Date:  2012-04-26

6.  Long-Term Survival of a Patient with Brainstem and Recurrent Brain Metastasis from Stage IV Nonsmall Cell Lung Cancer Treated with Multiple Gamma Knife Radiosurgeries and Craniotomies: A Case Report and Review of the Literature.

Authors:  Andrew F Lamm; Ameer L Elaimy; Alexander R Mackay; Robert K Fairbanks; John J Demakas; Barton S Cooke; Christopher M Lee; Blake S Taylor; Wayne T Lamoreaux
Journal:  Case Rep Oncol Med       Date:  2012-09-29

7.  Multimodality treatment of brain metastases: an institutional survival analysis of 275 patients.

Authors:  Ameer L Elaimy; Alexander R Mackay; Wayne T Lamoreaux; Robert K Fairbanks; John J Demakas; Barton S Cooke; Benjamin J Peressini; John T Holbrook; Christopher M Lee
Journal:  World J Surg Oncol       Date:  2011-07-05       Impact factor: 2.754

8.  Erlotinib intercalating pemetrexed/cisplatin versus erlotinib alone in Chinese patients with brain metastases from lung adenocarcinoma: a prospective, non-randomised, concurrent controlled trial (NCT01578668).

Authors:  Haihong Yang; Qiuhua Deng; Yuan Qiu; Jun Huang; Yubao Guan; Fengnan Wang; Xin Xu; Xinyun Yang
Journal:  ESMO Open       Date:  2017-03-07

9.  A review of the clinical outcomes for patients diagnosed with brainstem metastasis and treated with stereotactic radiosurgery.

Authors:  Andrew F Lamm; Ameer L Elaimy; Wayne T Lamoreaux; Alexander R Mackay; Robert K Fairbanks; John J Demakas; Barton S Cooke; Christopher M Lee
Journal:  ISRN Surg       Date:  2013-04-11

10.  Combined primary tumor and extracranial metastasis status as constituent factor of prognostic indices for predicting the overall survival in patients with brain metastases.

Authors:  Young Hee Park; Tae Hyun Kim; Sun-Young Jung; Young-Eun Kim; Jong-Myon Bae; Yeon-Joo Kim; Ji Hoon Choi; Nam Kwon Lee; Sung Ho Moon; Sang Soo Kim; Kyung Hwan Shin; Joo-Young Kim; Dae Yong Kim; Kwan Ho Cho
Journal:  J Korean Med Sci       Date:  2013-01-29       Impact factor: 2.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.